Andrew Cooke

Discovery of OSI-906: A Selective and Orally Efficacious Dual Inhibitor of the IGF-1 Receptor and Insulin Receptor

Mark J. Mulvihill, Andrew Cooke, Maryland Rosenfeld-Franklin et al. · Future Medicinal Chemistry · 2009 · 307 citations · Full text

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling <i>in vitro</i> and inhibits insulin-like growth factor-I receptor–dependent tumor growth <i>in vivo</i>

Qunsheng Ji, Mark J. Mulvihill, Maryland Rosenfeld-Franklin et al. · Molecular Cancer Therapeutics · 2007 · 147 citations · Full text

Igf-ii Expression, Signal Transduction, Growth Hormone +14

OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

Andrew J. Garton, Andrew P. Crew, Maryland Franklin et al. · Cancer Research · 2006 · 80 citations · Full text

Mouse Xenograft Models, Antitumor Activity, Chemoprevention Strategy +18

Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors

Mark J. Mulvihill, Qunsheng Ji, Heather Coate et al. · Bioorganic & Medicinal Chemistry · 2007 · 72 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +9

SAR, Pharmacokinetics, Safety, and Efficacy of Glucokinase Activating 2-(4-Sulfonylphenyl)-<i>N</i>-thiazol-2-ylacetamides: Discovery of PSN-GK1

L. Bertram, Daniel Black, Paul Briner et al. · Journal of Medicinal Chemistry · 2008 · 54 citations · Full text

Pharmaceutical Science, Glycobiology, Robust Glucose +19